From Barron's 8-6-07: Buy 2 - Price 94.98 on July 31 by UBS Investment Research "This real-estate investment trust's portfolio...of Class-A office properties includ[es] two hotels...Its strategy to sell assets and reinvest the proceeds into higher-yielding developments and debt reduction should accelerate earnings growth in '09 and beyond. Rents continue to rise in BXP's markets...BXP trades at [a] 27% discount to our '08 [estimated net asset value]. Target: 117...."

From Barron's 8-6-07: Buy - Price 16.13 on Aug. 1 by Wedbush Morgan "Headwaters [develops coal products...for construction materials, combustion and alternative energy]...With Ebitda multiples in the range of seven to 10 times across its various operations on our FY09 estimates, we derive our price target of 22 (up from 21), implying 14.7 times P/E multiple on our FY09 [earnings-per-share] estimate of $1.50. While sentiments remain negative on residential housing, we believe [they] are likely already reflected in the valuation...Should a sustained rebound occur in housing and [greater] commercialization efforts of HW's new technologies beyond coal-cleaning materialize, our estimates...could prove conservative."

From Barron's 8-6-07: Buy - Price 18 on July 31 by Jesup & Lamont "Target of 24 is based on sum-of-parts valuation...Founded in 1990 by MIT roboticists...IRBT designs, manufactures and markets robots to perform tasks [from] floor-cleaning [to] life-endangering missions like bomb retrieval....We expect a spate [of new products] in second-half '07. In 2008 time frame, on the military side of the business, we...look forward to increased diversification [via] new products and, eventually, profitability....We forecast IRBT's revenue will grow 27% to $240 million in 2007, and 23% to $295.2 million. We believe IRBT is a pure-play robotics company [with] unlimited end-market demand."

From Barron's 8-6-07: Market Outperform - Price 2.97 on July 31 by Rodman & Renshaw "Novavax...[has begun] the first human clinical trial of virus-like-particle-based pandemic influenza vaccine. We believe [its]...technology represents one of the most promising alternatives to traditional egg-based and mammalian cell-based systems...With [improving] fundamentals...Novavax is well-positioned to achieve its 2007 milestones. We believe it presents an attractive value. Target: 10. Market cap: $170 million."

From Barron's 8-6-07: Underperform - Price 27.04 on August 3 by RBC Capital Markets "Considering [this energy-holding company's] continuing saga of unplanned outages and disappointing [year-to-date] earnings, we are downgrading to Underperform from Sector Perform. PNM has vowed to improve operations and lower costs many times, but [has] not yet realized its goals...We are lowering our target to $24 from $34 and our CNAV to $30 from $39. PNM lowered 2007 EPS guidance to $1.30-$1.50 from $1.80-$2.00, indicative of its present situation. We echo PNM's sentiment and lower our 2007E EPS to $1.40 from $1.96."

From Barron's 8-6-07: Hold - Price 58.47 on Aug. 1 by McAdams Wright Ragen "[Insurer] Safeco reported Q2 operating earnings of $1.65 per share, better than our estimate of $1.50 and down slightly from the $1.71 earned in Q2 a year ago. Share buybacks, expense controls and lower catastrophe losses helped offset higher loss costs and a decline in favorable prior-year-reserve development. We have fine-tuned our 2007 EPS estimate to $6.45 from $6.30, mainly [on] better-than-expected Q2 EPS figures."

From Barron's 8-6-07: Buy - Price 11.75 on July 31 by Deutsche Bank "Target: 15. Q2 was roughly in-line w/ expectations. SSCC points to adjusted (non-GAAP) [earnings of] 6 cents -- but included roughly 3 cents from emission-credits sale...Q2 box volumes were down 6.7%, below 1.7% industry decline. Prices rose quarter-over-quarter for containerboard and corrugated boxes...Remains a "show-me" [stock], but with substantial potential...Estimates: Keeping '07 at 20 cents, 3Q at 9 cents."

From Barron's 8-6-07: Market Outperform - Price C43.85 on July 31 by Dundee Securities Research "TSX Group operates Canada's two national stock exchanges, an energy-trading platform and a significant interest in electronic fixed-income trading. Its core reported earnings for the quarter were C60 cents, above consensus of C58 cents and our C59 cents. This represents modest growth on a sequential (up 4%) and year-over-year (up 5%) basis...Increasing our target to C$56 (from C$50) -- reflecting a 16.9 times multiple to our 2008 adjusted-earnings forecast."